Anthrax Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Anthrax Vaccine Market is Segmented by Vaccine Type (Cell-Free PA Vaccine and Live Attenuated Vaccine), Application Type (Animal Use and Human Use), Distribution Channel (Hospitals, Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

anthrax vaccine market
Study Period: 2018-2026
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 7.85 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The anthrax vaccine market is expected to project growth with an estimated CAGR of 7.85% during the forecast period.

All the markets were majorly impacted by the sudden outbreak of COVID-19. With the focus primarily shifted to combat COVID-19, all other research and development are put on hold. In July 2020, the Center for Disease Control and Prevention (CDC) had provided certain guidelines to veterinary professionals for the treatment of animals during COVID-19. Along with these, many government agencies have recommended prioritizing urgent and emergency visits to clinics and hospitals. Thus, COVID-19 is expected to have a slight negative impact on the anthrax vaccine market.

The studied market growth is largely attributed to factors, such as the increasing prevalence rate of anthrax and rising consumption of undercooked or raw meat. Anthrax is a serious public health problem and causes high economic significance in affected countries. Enhancing surveillance, diagnosis, and outbreak response may help to prevent it in both animals and humans. The prevalence rate of disease is high, the risk and severity of infection make it one of the priority list diseases for preventive healthcare agencies. In December 1999, the Centers for Disease Control and Prevention (CDC) launched the Anthrax Vaccine Research Program (AVRP) and continue working till now to encourage studies about cost-effective, next-generation anthrax vaccines and measure the ability for provoking an immunological response. Anthrax from contaminated meat has been reported in animals as well. Furthermore, according to the Agricultural Economic Insights (AEI) report, meat consumption in the United States increased in 2020 when studied from 1970 to 2020. Although consumption pattern largely varies in poultry, beef, and pork, it increases the risk of anthrax. Thus, concerning the above facts, the anthrax vaccine market is expected to grow over the forecast period.

Although the market is dominated by limited players and expected to grow in the forecast period, factors, such as less awareness about diagnostic and screening tests and the cost-prohibitive nature of the anthrax vaccine, may restrict the market growth.

Scope of the Report

As per the scope of this report, anthrax is an infectious disease caused by gram-positive, rod-shaped bacteria called Bacillus anthracis. It is a rare but serious infection and may affect both animals and humans. Humans and animals get infected when spores enter their bodies through inhalation, contaminated food, soil, cut, or scrape in the skin. According to the Health Protection Surveillance Center, 95% of infection in humans occurs through cutaneous means due to direct contact with infected animal’s skin or tissue. The two major forms of the vaccine are available for human use: one of which is cell-free filtrate, and the other is live attenuated, which can be administered by subcutaneous and intramuscular routes. The anthrax vaccine market is segmented by vaccine type (cell-free PA vaccine and live attenuated vaccine), application type (animal use and human use), distribution channel (hospitals, pharmacies, and other distribution channels), and geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Vaccine Type
Cell Free PA Vaccine
Anthrax Vaccine Absorbed (AVA)
Anthrax Vaccine Precipitated (AVP)
Live Attenuated Vaccine
By Applications
Animal Use
Human Use
By Distribution Channel
Other Distribution Channels
By Geography
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Animal Use Anthrax Vaccination Segment is Expected to Dominate the Market Over the Forecast Period

Anthrax is an epizootics disease spread from animals to humans and emerges periodically among susceptible animals, either wild or domesticated. In herbivore animals, like cattle, sheep, goats, camels, and antelopes, anthrax is acute septicemia with a high fatality rate and is usually accompanied by hemorrhagic lymphadenitis. On the other hand, it is a less acute but potentially fatal disease in dogs, pigs, and horses. The appearance of the outbreak may be associated with drought, flood, or soil disturbances. Humans got anthrax infection when they encountered infected animals or their processed materials, like wool, processed hair, etc. The annual vaccination is required in animals before 2-4 weeks of the season when the outbreak is expected. Many anthrax vaccines are used for animals and all of which are un-encapsulated live variant vaccines. The live vaccines used for animals require a withholding period to slaughter for human consumption, which varies from 3-6 weeks depending on the vaccine used. Additionally, Bacillus anthracis spores have been used earlier as biologic warfare agents and are a threat to both animal and human populations. Therefore, vaccination in animals, particularly in livestock, is considered a vital tool for preventing and controlling anthrax cases both in animals and humans.

Anthrax vaccine market 2

North America Holds Significant Share in the Market and Expected to Grow in Forecast Period

Anthrax is most common in agricultural regions with calcareous soil and has been reported almost in every continent. In North America, anthrax infection is rare. According to the United States Food and Drug Administration (USFDA) February 2018 report, the mortality rates vary according to the exposure. It is 20% for cutaneous anthrax without antibiotics, for gastrointestinal anthrax, it can 25-75%. The fatality rate could 80% or higher for inhalational anthrax. The major sources of infection in humans are direct contact with infected animals, animal products. The effective vaccination for adults of 18-65 age by Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston with occupational risk of anthrax exposure. Due to the lethality of disease and potential bioterrorism agents, vaccination is highly needed. Therefore, federal agencies are continuously taking steps to prevent anthrax and focus mainly on vaccination programs. Further, according to the priority pathogen list, July 2018, Bacillus Anthracis is a Category A priority pathogen developed by the National Institute of Allergy and Infectious Disease (NIAID), the United States which implies it poses the highest risk to National security. Thus, North America is encouraging participates to enter in North America Market by focusing more on preventive healthcare facilities.

Anthrax Vaccine Market 2

Competitive Landscape

The anthrax vaccine market is consolidated with a limited number of players both in the human and animal segments. In terms of market share, major players dominate the market. With the rising prevalence of disease and increasing awareness among the public, many new players may enter the market over the forecast period. Some major market players under the human anthrax vaccine segment are Emergent Bio Solutions, Altimmune, and Proton Biopharma Ltd, while the animal segment of the market is dominated by Colondo Serum Company, Zoetis Inc, and Bayer AG.

Recent Developments

In August 2020, Elusys Therapeutics Inc. (Elusys) got approval from Health Canada for Anthim (obiltoxaximab for injection) monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax. It can be used in both adults and pediatrics for post-exposure prophylaxis treatment.

In August 2020, a pilot study was completed for the first oral anthrax vaccine for livestock by Dr. Jamie Benn Felix and the Cook Wildlife Lab team with Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVMBS).

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Anthrax Globally

      2. 4.2.2 Increased Consumption of Undercooked/Raw Meat

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness for Diagnostic Test of Target Disease

      2. 4.3.2 High Cost Associated with Vaccine

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Vaccine Type

      1. 5.1.1 Cell Free PA Vaccine

        1. Anthrax Vaccine Absorbed (AVA)

        2. Anthrax Vaccine Precipitated (AVP)

      2. 5.1.2 Live Attenuated Vaccine

    2. 5.2 By Applications

      1. 5.2.1 Animal Use

      2. 5.2.2 Human Use

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospitals

      2. 5.3.2 Pharmacies

      3. 5.3.3 Other Distribution Channels

    4. 5.4 By Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Emergent Bio Solutions

      2. 6.1.2 Altimmune (PharmAthene Inc.)

      3. 6.1.3 Proton Biopharma Ltd

      4. 6.1.4 Colondo Serum Company

      5. 6.1.5 Merck & Co. Inc.

      6. 6.1.6 Bayer AG

      7. 6.1.7 Zoetis Inc.

      8. 6.1.8 Indian Immunologics

      9. 6.1.9 Agrovet

      10. 6.1.10 Biogenesis Bago

      11. 6.1.11 Tiankang

    2. *List Not Exhaustive

**Competitive Landscape covers Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Anthrax Vaccine Market market is studied from 2018 - 2026.

The Global Anthrax Vaccine Market is growing at a CAGR of 7.85% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Emergent Bio Solutions , Proton Biopharma , Colondo Serum Company , Altimmune (PharmAthene Inc.), Merck Co, Inc. (MSD Animal Health) are the major companies operating in Global Anthrax Vaccine Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!